

**Clinical trial results:****A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis  
Summary**

EudraCT number	2010-020338-25
Trial protocol	LT ES BE FR HU NL CZ GB DE PT AT FI IT GR BG DK PL
Global end of trial date	31 December 2022

**Results information**

Result version number	v3 (current)
This version publication date	03 January 2024
First version publication date	08 July 2016
Version creation reason	

**Trial information****Trial identification**

Sponsor protocol code	WA25046
-----------------------	---------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01194570
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Hoffmann-La Roche
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, 4070
Public contact	F. Hoffmann-La Roche, Ltd, F. Hoffmann-La Roche, Ltd, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche, Ltd, Hoffmann-La Roche, +41 616878333, global.trial_information@roche.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 December 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 December 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This randomized, parallel group, double-blind, placebo controlled study evaluated the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants were randomized 2 : 1 to receive either ocrelizumab or placebo.

Protection of trial subjects:

This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. All participants were required to read and sign an informed consent form prior to participation in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	Austria: 16
Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	Bulgaria: 3
Country: Number of subjects enrolled	Brazil: 11
Country: Number of subjects enrolled	Canada: 32
Country: Number of subjects enrolled	Switzerland: 7
Country: Number of subjects enrolled	Czechia: 20
Country: Number of subjects enrolled	Germany: 57
Country: Number of subjects enrolled	Spain: 74
Country: Number of subjects enrolled	Finland: 12
Country: Number of subjects enrolled	France: 106
Country: Number of subjects enrolled	United Kingdom: 29
Country: Number of subjects enrolled	Greece: 7
Country: Number of subjects enrolled	Hungary: 20
Country: Number of subjects enrolled	Israel: 17
Country: Number of subjects enrolled	Italy: 15
Country: Number of subjects enrolled	Lithuania: 5
Country: Number of subjects enrolled	Mexico: 6

Country: Number of subjects enrolled	Netherlands: 11
Country: Number of subjects enrolled	Norway: 1
Country: Number of subjects enrolled	New Zealand: 2
Country: Number of subjects enrolled	Peru: 5
Country: Number of subjects enrolled	Poland: 58
Country: Number of subjects enrolled	Romania: 8
Country: Number of subjects enrolled	Russian Federation: 2
Country: Number of subjects enrolled	Ukraine: 74
Country: Number of subjects enrolled	United States: 101
Country: Number of subjects enrolled	Portugal: 18
Worldwide total number of subjects	732
EEA total number of subjects	436

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	732
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 943 participants were screened and 732 were randomized into the study, of which 725 received at least one dose of placebo or ocrelizumab.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.

Investigational medicinal product name	Ocrelizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.

<b>Arm title</b>	Ocrelizumab 600 mg
------------------	--------------------

Arm description:

Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.

Arm type	Experimental
Investigational medicinal product name	Ocrelizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.

<b>Number of subjects in period 1</b>	Placebo	Ocrelizumab 600 mg
Started	244	488
Completed	89	218
Not completed	155	270
Adverse event, serious fatal	6	20
Consent withdrawn by subject	57	82
Physician decision	10	25
Non-Compliance	2	2
Adverse event, non-fatal	22	40
Study Terminated By Sponsor	-	1
Pregnancy	1	1
Non-Compliance With Study Drug	2	2
Not Specified	18	47
Lost to follow-up	4	15
Lack of efficacy	32	33
Protocol deviation	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.	
Reporting group title	Ocrelizumab 600 mg
Reporting group description:	
Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.	

Reporting group values	Placebo	Ocrelizumab 600 mg	Total
Number of subjects	244	488	732
Age Categorical			
Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	244	488	732
>=65 years	0	0	0
Age Continuous			
Units: years			
arithmetic mean	44.4	44.7	
standard deviation	± 8.3	± 7.9	-
Gender, Male/Female			
Units:			
Female	124	237	361
Male	120	251	371
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	5	5
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	5	9	14
White	235	454	689
More than one race	0	0	0
Unknown or Not Reported	4	20	24
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	14	32	46
Not Hispanic or Latino	206	385	591
Unknown or Not Reported	24	71	95

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.	
Reporting group title	Ocrelizumab 600 mg
Reporting group description: Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.	
Subject analysis set title	Placebo (Open Label Extension)
Subject analysis set type	Sub-group analysis
Subject analysis set description: During the OLE phase, all participants received ocrelizumab 600-mg IV infusion every 24 weeks.	
Subject analysis set title	Ocrelizumab (Open Label Extension)
Subject analysis set type	Sub-group analysis
Subject analysis set description: During the OLE phase, all participants received ocrelizumab 600-mg IV infusion every 24 weeks.	

### Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at least 12 Weeks During the Double-Blind Treatment Period

End point title	Time to Onset of Clinical Disability Progression (CDP) Sustained for at least 12 Weeks During the Double-Blind Treatment Period <sup>[1]</sup>
End point description: The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit $\geq 12$ weeks ( $\geq 84$ days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of $\geq 1.0$ point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is $\leq 5.5$ points (inclusive), or an increase of $\geq 0.5$ points, if baseline EDSS is $> 5.5$ points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.	
End point type	Primary
End point timeframe: Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Final results	

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	244 <sup>[2]</sup>	487 <sup>[3]</sup>		
Units: weeks				
median (full range (min-max))	0000 (0 to 0000)	0000 (0 to 0000)		

Notes:

[2] - Not reached due to low number of participants with the event at the end of the study.

[3] - Not reached due to low number of participants with the event at the end of the study.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period

End point title	Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period
-----------------	---

End point description:

The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit  $\geq 12$  weeks ( $\geq 84$  days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of  $\geq 1.0$  point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is  $\leq 5.5$  points (inclusive), or an increase of  $\geq 0.5$  points, if baseline EDSS is  $> 5.5$  points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	244 <sup>[4]</sup>	487 <sup>[5]</sup>		
Units: weeks				
median (full range (min-max))	0000 (0 to 0000)	0000 (0 to 0000)		

Notes:

[4] - Not reached due to low number of participants with the event at the end of the study.

[5] - Not reached due to low number of participants with the event at the end of the study.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120

End point title	Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 120

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	473		
Units: percent change				
least squares mean (confidence interval 95%)	55.097 (39.855 to 71.999)	38.933 (29.222 to 49.374)		

## Statistical analyses

Statistical analysis title	Ranked ANCOVA
----------------------------	---------------

Statistical analysis description:

Estimates (back-transformed) based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix:  $\log(\text{Post-baseline(BL)}/\text{BL}) = \log(\text{BL 25-FTW}) + \text{Geographical Region (US vs. ROW)} + \text{Age } (<=45, > 45 \text{ years}) + \text{Week} + \text{Treatment} + \text{Treatment*Week (repeated values over Week)} + \log(\text{BL 25-FTW}) * \text{Week}$ . Relative reduction was calculated as  $-\text{Relative change} = -(\text{OCR response} - \text{Placebo response}) / \text{Placebo response} * 100\%$ . The 95% CI for relative reduction was obtained using the Bootstrap method.

Comparison groups	Placebo v Ocrelizumab 600 mg
Number of subjects included in analysis	712
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0404 <sup>[6]</sup>
Method	Ranked ANCOVA
Parameter estimate	Relative Reduction (%)
Point estimate	29.337
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.618
upper limit	51.456

Notes:

[6] - P-value from a ranked ANCOVA on Percent Change from BL adjusting for rank of BL 25-Foot Timed Walk (25-FTW), Geographical Region (US vs ROW) and Age (<=45, > 45 years); missing observations imputed with LOCF.

## Secondary: Percent Change From Baseline in Total Volume of T2 Lesions at Week 120

End point title	Percent Change From Baseline in Total Volume of T2 Lesions at Week 120
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Week 120

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	234	464		
Units: percent change				
least squares mean (confidence interval 95%)	7.426 (4.967 to 9.942)	-3.366 (-4.987 to -1.718)		

## Statistical analyses

Statistical analysis title	Ranked ANCOVA
----------------------------	---------------

Statistical analysis description:

Estimates (back-transformed) are based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix:  $\log(\text{Post-BL/BL}) = \log(\text{BL T2 lesion volume}) + \text{Geographical Region (US vs. ROW)} + \text{Age } (<=45, > 45 \text{ years}) + \text{Week} + \text{Treatment} + \text{Treatment*Week (repeated values over Week)} + \log(\text{BL T2 lesion volume}) * \text{Week}$ .

Comparison groups	Placebo v Ocrelizumab 600 mg
Number of subjects included in analysis	698
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001 <sup>[7]</sup>
Method	Ranked ANCOVA
Parameter estimate	Ratio of Adjusted Geometric Means
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.876
upper limit	0.924

Notes:

[7] - P-value is from ranked ANCOVA on Percent Change from BL adjusting for rank of BL T2 lesion volume, Geographical Region (US vs ROW) and Age (<=45, > 45 years); missing observations imputed with LOCF.

## Secondary: Percent Change in Total Brain Volume From Week 24 to Week 120

End point title	Percent Change in Total Brain Volume From Week 24 to Week 120
-----------------	---

End point description:

End point type	Secondary
End point timeframe:	
From Week 24 to Week 120	

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	203	407		
Units: percent change				
least squares mean (confidence interval 95%)	-1.093 (-1.236 to -0.951)	-0.902 (-1.004 to -0.799)		

## Statistical analyses

Statistical analysis title	MMRM
Statistical analysis description:	
Estimates are from analysis based on MMRM using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Age ( $\leq 45$ , $> 45$ years) + Week + Treatment + Treatment*Week (repeated values over Week) + Brain Volume at Week 24*Week. Relative reduction was calculated as - Relative change = - (OCR response-Placebo response)/Placebo response*100%. The 95% CI for relative reduction was obtained using Bootstrap method.	
Comparison groups	Placebo v Ocrelizumab 600 mg
Number of subjects included in analysis	610
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0206
Method	MMRM
Parameter estimate	Relative Reduction (%)
Point estimate	17.475
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.206
upper limit	29.251

## Secondary: Change in From Baseline Physical Component Summary Score (PCS) SF-36 Health Survey (SF-36) at Week 120

End point title	Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120
End point description:	
The SF-36v2 is a 36-item, self- reported, generic measure of quality of life that has been widely used in multiple disease areas. It is composed of 8 health domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The PCS score was derived based on the SF-36 V2 User's Manual. Scoring for PCS involves (a) recoding item response values, (b) summing recoded response values for all items in a given scale to obtain the scale raw score, (c) transforming scale raw score to a 0–100 score. The PCS score was computed by (a) multiplying each health domain z score by a scale-specific physical factor score coefficient, (b) summing the resulting products, (c) converting the product total to T score. The total score ranges from 0-100, higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	
End point type	Secondary
End point timeframe:	
From Baseline to Week 120	

End point values	Placebo	Ocrelizumab 600 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	292		
Units: units on a scale				
least squares mean (confidence interval 95%)	-1.108 (-2.394 to 0.177)	-0.731 (-1.655 to 0.193)		

## Statistical analyses

Statistical analysis title	MMRM
Statistical analysis description:	
Estimates are from analysis based on MMRM using unstructured covariance matrix: Change = Baseline PCS Score + Geographical Region (US vs. ROW) + Age (<=45, > 45 years) + Week + Treatment + Treatment*Week (repeated values over Week) + Baseline PCS Score*Week.	
Comparison groups	Placebo v Ocrelizumab 600 mg
Number of subjects included in analysis	420
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6034
Method	MMRM
Parameter estimate	Difference in Adjusted Means
Point estimate	0.377
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.048
upper limit	1.802
Variability estimate	Standard error of the mean
Dispersion value	0.725

## Secondary: Number of Participants With at Least one Adverse Event (AE)

End point title	Number of Participants With at Least one Adverse Event (AE)
End point description:	
AEs included infusion related reactions (IRRs) and serious multiple sclerosis (MS) relapses, but excluded non-serious MS relapses.	
End point type	Secondary
End point timeframe:	
From baseline to 9 years	

<b>End point values</b>	Placebo	Ocrelizumab 600 mg	Placebo (Open Label Extension)	Ocrelizumab (Open Label Extension)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	239	486	160	367
Units: Participants				
Serious Adverse Events	53	99	59	167
Adverse Events	215	462	148	354

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to 615 weeks

Adverse event reporting additional description:

The safety population included all participants who received any study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	DB PLACEBO
-----------------------	------------

Reporting group description:

Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.

Reporting group title	OLE OCRELIZUMAB
-----------------------	-----------------

Reporting group description:

During the OLE phase, all participants received ocrelizumab 600-mg IV infusion every 24 weeks.

Reporting group title	OLE PLACEBO
-----------------------	-------------

Reporting group description:

During the OLE phase, all participants received ocrelizumab 600-mg IV infusion every 24 weeks.

Reporting group title	DB OCRELIZUMAB
-----------------------	----------------

Reporting group description:

Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.

Serious adverse events	DB PLACEBO	OLE OCRELIZUMAB	OLE PLACEBO
Total subjects affected by serious adverse events			
subjects affected / exposed	58 / 239 (24.27%)	167 / 369 (45.26%)	59 / 158 (37.34%)
number of deaths (all causes)	7	19	4
number of deaths resulting from adverse events	0	3	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BORDERLINE SEROUS TUMOUR OF OVARY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAPLASTIC LARGE-CELL LYMPHOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

BASAL CELL CARCINOMA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BENIGN PANCREATIC NEOPLASM			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BENIGN VAGINAL NEOPLASM			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BLADDER CANCER			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
ADENOCARCINOMA OF THE CERVIX			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BREAST CANCER			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHONDROMA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENDOMETRIAL CANCER			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATIC NEOPLASM			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
INTRADUCTAL PAPILLARY BREAST NEOPLASM			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MALIGNANT FIBROUS HISTIOCYTOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INVASIVE DUCTAL BREAST CARCINOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
KERATOACANTHOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LIPOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUNG ADENOCARCINOMA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
LUNG NEOPLASM MALIGNANT			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INVASIVE BREAST CARCINOMA			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MENINGIOMA BENIGN</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NODULAR MELANOMA</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCREATIC CARCINOMA METASTATIC</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
<b>PARAGANGLION NEOPLASM BENIGN</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PARATHYROID TUMOUR BENIGN</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>RENAL CELL CARCINOMA</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ROSAI-DORFMAN SYNDROME</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SOFT TISSUE NEOPLASM</b>			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSITIONAL CELL CARCINOMA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UTERINE LEIOMYOMA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PROSTATE CANCER			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 239 (0.42%)	3 / 369 (0.81%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRY GANGRENE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VARICOSE VEIN			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSIVE CRISIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL ARTERY OCCLUSION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTENSION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CATHETER SITE HAEMORRHAGE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHEST PAIN			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DRUG INTOLERANCE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FATIGUE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GAIT DISTURBANCE			

subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASTHENIA			
subjects affected / exposed	1 / 239 (0.42%)	4 / 369 (1.08%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERTHERMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLAMMATION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUDDEN DEATH			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
SUDDEN CARDIAC DEATH			

subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
CERVICAL POLYP			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENDOMETRIAL HYPERPLASIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FIBROCYSTIC BREAST DISEASE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTERMENSTRUAL BLEEDING			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UTERINE PROLAPSE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OVARIAN CYST TORSION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

OVARIAN CYST			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPERSENSITIVITY PNEUMONITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPNOEA			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHRONIC OBSTRUCTIVE PULMONARY DISEASE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ALVEOLITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ASPIRATION			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
BRONCHITIS CHRONIC			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ACUTE PULMONARY OEDEMA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY THROMBOSIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY GRANULOMA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PULMONARY EMBOLISM			
subjects affected / exposed	0 / 239 (0.00%)	5 / 369 (1.36%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
PNEUMOTHORAX SPONTANEOUS			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMOTHORAX			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOCAL CORD THICKENING			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Psychiatric disorders</b>			
<b>BEHAVIOUR DISORDER</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ANXIETY</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PSYCHOTIC DISORDER</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SUICIDAL IDEATION</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SUICIDE ATTEMPT</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MENTAL STATUS CHANGES</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MANIA</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MAJOR DEPRESSION</b>			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DEPRESSION SUICIDAL</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DEPRESSION</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>COMPLETED SUICIDE</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
<b>Investigations</b>			
<b>BLOOD GLUCOSE FLUCTUATION</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HELICOBACTER TEST POSITIVE</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>LIVER FUNCTION TEST ABNORMAL</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
<b>ACCIDENTAL OVERDOSE</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

ANKLE FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC CONTUSION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURED SACRUM			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FALL			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
FEMORAL NECK FRACTURE			
subjects affected / exposed	1 / 239 (0.42%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEMUR FRACTURE			
subjects affected / exposed	2 / 239 (0.84%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FIBULA FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FRACTURE DISPLACEMENT			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONTUSION			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEAD INJURY			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST LUMBAR PUNCTURE SYNDROME			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HIP FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HUMERUS FRACTURE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INCISION SITE IMPAIRED HEALING			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFUSION RELATED REACTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
JOINT DISLOCATION			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUMBAR VERTEBRAL FRACTURE			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MULTIPLE FRACTURES			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OVERDOSE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PATELLA FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PELVIC FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST PROCEDURAL FEVER			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST PROCEDURAL HAEMATURIA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RADIUS FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ROAD TRAFFIC ACCIDENT			

subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
TENDON RUPTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUBDURAL HAEMATOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUBDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN LACERATION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TIBIA FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UPPER LIMB FRACTURE			

subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WOUND DEHISCENCE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WRIST FRACTURE			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANGINA UNSTABLE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ATRIAL FIBRILLATION			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BUNDLE BRANCH BLOCK LEFT			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC ARREST			
subjects affected / exposed	0 / 239 (0.00%)	3 / 369 (0.81%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 1
TACHYCARDIA			

subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIOMYOPATHY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
CORONARY ARTERY INSUFFICIENCY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MYOCARDIAL ISCHAEMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
SINUS TACHYCARDIA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CARDIAC FAILURE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
CEREBRAL INFARCTION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBRAL ISCHAEMIA			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CEREBROVASCULAR ACCIDENT			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EMBOLIC STROKE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPILEPSY			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GENERALISED TONIC-CLONIC SEIZURE			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MIGRAINE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEMIPARESIS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTRACRANIAL ANEURYSM			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INTRACRANIAL PRESSURE INCREASED			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LUMBAR RADICULOPATHY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEADACHE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MIGRAINE WITH AURA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MULTIPLE SCLEROSIS			
subjects affected / exposed	0 / 239 (0.00%)	4 / 369 (1.08%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
MULTIPLE SCLEROSIS PSEUDO RELAPSE			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MULTIPLE SCLEROSIS RELAPSE			
subjects affected / exposed	2 / 239 (0.84%)	4 / 369 (1.08%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCLE SPASTICITY			
subjects affected / exposed	2 / 239 (0.84%)	3 / 369 (0.81%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NERVOUS SYSTEM DISORDER			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OPTIC NEURITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARALYSIS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARAPARESIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARKINSON'S DISEASE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PARTIAL SEIZURES WITH SECONDARY GENERALISATION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PRESYNCOPE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SCIATICA			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEIZURE			
subjects affected / exposed	2 / 239 (0.84%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STATUS EPILEPTICUS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUBARACHNOID HAEMORRHAGE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRANSIENT ISCHAEMIC ATTACK			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UHTHOFF'S PHENOMENON			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TRIGEMINAL NEURALGIA			
subjects affected / exposed	1 / 239 (0.42%)	2 / 369 (0.54%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SYNCOPE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
AGRANULOCYTOSIS			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAEMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAEMIA MEGALOBLASTIC			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IRON DEFICIENCY ANAEMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LYMPHADENOPATHY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MICROCYTIC ANAEMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FEBRILE NEUTROPENIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
CATARACT			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPIRETINAL MEMBRANE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EYE INFLAMMATION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GLAUCOMA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RETINAL DISORDER			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
APHTHOUS ULCER			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAL FISSURE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANAL POLYP			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ANORECTAL VARICES			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ABDOMINAL PAIN			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COLITIS ISCHAEMIC			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	2 / 239 (0.84%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CROHN'S DISEASE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRIC ULCER HAEMORRHAGE			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DUODENAL ULCER			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DUODENAL ULCER HAEMORRHAGE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENTEROCOLITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
FAECALOMA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRIC FISTULA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIVERTICULUM			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTRITIS EROSIVE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROINTESTINAL INFLAMMATION			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>GASTROINTESTINAL POLYP HAEMORRHAGE</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ILEUS</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INCARCERATED UMBILICAL HERNIA</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PANCREATITIS ACUTE</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>LARGE INTESTINE POLYP</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NAUSEA</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>OESOPHAGEAL RUPTURE</b>			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PANCREATITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INGUINAL HERNIA			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UMBILICAL HERNIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOLVULUS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VOMITING			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
CHOLECYSTITIS CHRONIC			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BILE DUCT STENOSIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CHOLANGITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CHOLECYSTITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CHOLECYSTITIS ACUTE</b>			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>DRUG-INDUCED LIVER INJURY</b>			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HEPATITIS ACUTE</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HEPATITIS TOXIC</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CHOLELITHIASIS</b>			

subjects affected / exposed	1 / 239 (0.42%)	2 / 369 (0.54%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
PRURITUS ALLERGIC			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ACTINIC KERATOSIS			
subjects affected / exposed	2 / 239 (0.84%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DECUBITUS ULCER			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DERMATITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LICHEN PLANUS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RASH			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CALCULUS URINARY			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BLADDER PERFORATION</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>URETHRAL STENOSIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>URINARY RETENTION</b>			
subjects affected / exposed	2 / 239 (0.84%)	3 / 369 (0.81%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CYSTITIS HAEMORRHAGIC</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>TUBULOINTERSTITIAL NEPHRITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>PROTEINURIA</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>NEPHROLITHIASIS</b>			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYDRONEPHROSIS</b>			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMATURIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BACK PAIN			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CHONDROPATHY			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCLE SPASMS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RHABDOMYOLYSIS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEOARTHRITIS			

subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POLYARTHRITIS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ROTATOR CUFF SYNDROME			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SERONEGATIVE ARTHRITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL PAIN			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SPINAL STENOSIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
TENDONITIS			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>ABSCCESS OF EYELID</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ANAL ABSCCESS</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>APPENDICITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	3 / 369 (0.81%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	1 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>APPENDICITIS PERFORATED</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ARTHRITIS INFECTIVE</b>			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>ABSCCESS LIMB</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BACTERIAL INFECTION</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BACTERIAL PYELONEPHRITIS</b>			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BORRELIA INFECTION</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BRONCHIOLITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>BRONCHITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>COVID-19</b>			
subjects affected / exposed	0 / 239 (0.00%)	12 / 369 (3.25%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	2 / 12	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CANDIDA SEPSIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CELLULITIS</b>			
subjects affected / exposed	0 / 239 (0.00%)	5 / 369 (1.36%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	5 / 8	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CHOLECYSTITIS INFECTIVE</b>			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CLOSTRIDIUM DIFFICILE COLITIS</b>			

subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CLOSTRIDIUM DIFFICILE INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BURSITIS INFECTIVE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 PNEUMONIA			
subjects affected / exposed	0 / 239 (0.00%)	31 / 369 (8.40%)	5 / 158 (3.16%)
occurrences causally related to treatment / all	0 / 0	8 / 31	1 / 6
deaths causally related to treatment / all	0 / 0	2 / 5	0 / 0
CYSTITIS			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DENGUE FEVER			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIVERTICULITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ENCEPHALITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
GASTROINTESTINAL INFECTION			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ERYSIPELAS			
subjects affected / exposed	0 / 239 (0.00%)	3 / 369 (0.81%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ESCHERICHIA URINARY TRACT INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GANGRENE			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
GASTROENTERITIS VIRAL			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
EPIDIDYMITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HEPATITIS VIRAL			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HERPES OPHTHALMIC			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
IMPETIGO			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFECTED DERMAL CYST			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
INFLUENZA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ORCHITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MASTITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGITIS ASEPTIC			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MENINGITIS BACTERIAL			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NEUTROPENIC SEPSIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
LARGE INTESTINE INFECTION			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OSTEOMYELITIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OTITIS EXTERNA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PELVIC INFLAMMATORY DISEASE			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERITONITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA			
subjects affected / exposed	3 / 239 (1.26%)	17 / 369 (4.61%)	3 / 158 (1.90%)
occurrences causally related to treatment / all	1 / 4	8 / 18	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS			

subjects affected / exposed	1 / 239 (0.42%)	3 / 369 (0.81%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	1 / 1	3 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA BACTERIAL			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA ESCHERICHIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST PROCEDURAL INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
POST PROCEDURAL SEPSIS			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELOCYSTITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PNEUMONIA ASPIRATION			
subjects affected / exposed	0 / 239 (0.00%)	3 / 369 (0.81%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYELONEPHRITIS ACUTE			
subjects affected / exposed	0 / 239 (0.00%)	4 / 369 (1.08%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPSIS			

subjects affected / exposed	0 / 239 (0.00%)	7 / 369 (1.90%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	0 / 0	5 / 10	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
SEPTIC SHOCK			
subjects affected / exposed	1 / 239 (0.42%)	1 / 369 (0.27%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SINUSITIS			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SUSPECTED COVID-19			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
TOOTH INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URINARY TRACT INFECTION			
subjects affected / exposed	4 / 239 (1.67%)	20 / 369 (5.42%)	7 / 158 (4.43%)
occurrences causally related to treatment / all	1 / 5	9 / 28	1 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
UROSEPSIS			
subjects affected / exposed	2 / 239 (0.84%)	7 / 369 (1.90%)	2 / 158 (1.27%)
occurrences causally related to treatment / all	2 / 2	1 / 7	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VESTIBULAR NEURONITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIRAL INFECTION			

subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIRAL PERICARDITIS			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIRAL UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WOUND INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	0 / 369 (0.00%)	1 / 158 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ZIKA VIRUS INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 239 (0.42%)	0 / 369 (0.00%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DEHYDRATION			
subjects affected / exposed	0 / 239 (0.00%)	2 / 369 (0.54%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPONATRAEMIA			
subjects affected / exposed	0 / 239 (0.00%)	1 / 369 (0.27%)	0 / 158 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	DB OCRELIZUMAB		
Total subjects affected by serious adverse events			
subjects affected / exposed	104 / 486 (21.40%)		
number of deaths (all causes)	24		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
BORDERLINE SEROUS TUMOUR OF OVARY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANAPLASTIC LARGE-CELL LYMPHOMA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
BASAL CELL CARCINOMA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BENIGN PANCREATIC NEOPLASM			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BENIGN VAGINAL NEOPLASM			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BLADDER CANCER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ADENOCARCINOMA OF THE CERVIX			

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>BREAST CANCER</b>				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
<b>CHONDROMA</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>ENDOMETRIAL CANCER</b>				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>HEPATIC NEOPLASM</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>INTRADUCTAL PAPILLARY BREAST NEOPLASM</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>MALIGNANT FIBROUS HISTIOCYTOMA</b>				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>INVASIVE DUCTAL BREAST CARCINOMA</b>				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
<b>KERATOACANTHOMA</b>				

subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
LIPOMA				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
LUNG ADENOCARCINOMA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUNG NEOPLASM MALIGNANT				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INVASIVE BREAST CARCINOMA				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
MENINGIOMA BENIGN				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NODULAR MELANOMA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PANCREATIC CARCINOMA METASTATIC				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
PARAGANGLION NEOPLASM BENIGN				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PARATHYROID TUMOUR BENIGN			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RENAL CELL CARCINOMA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ROSAI-DORFMAN SYNDROME			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SOFT TISSUE NEOPLASM			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TRANSITIONAL CELL CARCINOMA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UTERINE LEIOMYOMA			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
PROSTATE CANCER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
DEEP VEIN THROMBOSIS			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DRY GANGRENE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
VARICOSE VEIN			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERTENSIVE CRISIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
PERIPHERAL ARTERY OCCLUSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERTENSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

CATHETER SITE HAEMORRHAGE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CHEST PAIN				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
DRUG INTOLERANCE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FATIGUE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GAIT DISTURBANCE				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
ASTHENIA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HYPERTHERMIA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INFLAMMATION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NON-CARDIAC CHEST PAIN				

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
OEDEMA PERIPHERAL			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
PYREXIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SUDDEN DEATH			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SUDDEN CARDIAC DEATH			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
DRUG HYPERSENSITIVITY			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
CERVICAL POLYP			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ENDOMETRIAL HYPERPLASIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

FIBROCYSTIC BREAST DISEASE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
INTERMENSTRUAL BLEEDING			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
UTERINE PROLAPSE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
OVARIAN CYST TORSION			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
OVARIAN CYST			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HYPERSENSITIVITY PNEUMONITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DYSPNOEA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

CHRONIC OBSTRUCTIVE PULMONARY DISEASE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ALVEOLITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ASPIRATION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
BRONCHITIS CHRONIC				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ACUTE RESPIRATORY FAILURE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ACUTE PULMONARY OEDEMA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PULMONARY THROMBOSIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PULMONARY GRANULOMA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PULMONARY EMBOLISM				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMOTHORAX SPONTANEOUS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PNEUMOTHORAX			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VOCAL CORD THICKENING			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PLEURAL EFFUSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
BEHAVIOUR DISORDER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANXIETY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PSYCHOTIC DISORDER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SUICIDAL IDEATION			

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SUICIDE ATTEMPT			
subjects affected / exposed	3 / 486 (0.62%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
MENTAL STATUS CHANGES			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MANIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MAJOR DEPRESSION			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
DEPRESSION SUICIDAL			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DEPRESSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COMPLETED SUICIDE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
BLOOD GLUCOSE FLUCTUATION			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HELICOBACTER TEST POSITIVE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
LIVER FUNCTION TEST ABNORMAL			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
ACCIDENTAL OVERDOSE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANKLE FRACTURE			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
CARDIAC CONTUSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FRACTURED SACRUM			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FALL			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FEMORAL NECK FRACTURE			

subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FEMUR FRACTURE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FIBULA FRACTURE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
FRACTURE DISPLACEMENT				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
CONTUSION				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
HEAD INJURY				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
POST LUMBAR PUNCTURE SYNDROME				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
HIP FRACTURE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HUMERUS FRACTURE				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INCISION SITE IMPAIRED HEALING				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INFUSION RELATED REACTION				
subjects affected / exposed	5 / 486 (1.03%)			
occurrences causally related to treatment / all	5 / 5			
deaths causally related to treatment / all	0 / 0			
JOINT DISLOCATION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LUMBAR VERTEBRAL FRACTURE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MULTIPLE FRACTURES				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
OVERDOSE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PATELLA FRACTURE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PELVIC FRACTURE				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
POST PROCEDURAL FEVER			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
POST PROCEDURAL HAEMATURIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RADIUS FRACTURE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ROAD TRAFFIC ACCIDENT			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TENDON RUPTURE			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
SUBDURAL HAEMATOMA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SUBDURAL HAEMORRHAGE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SKIN LACERATION			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
THORACIC VERTEBRAL FRACTURE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TIBIA FRACTURE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UPPER LIMB FRACTURE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
WOUND DEHISCENCE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
WRIST FRACTURE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
ACUTE MYOCARDIAL INFARCTION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANGINA UNSTABLE			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ATRIAL FIBRILLATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BUNDLE BRANCH BLOCK LEFT			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIAC ARREST			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TACHYCARDIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CARDIOMYOPATHY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CORONARY ARTERY INSUFFICIENCY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MYOCARDIAL INFARCTION			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
MYOCARDIAL ISCHAEMIA			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>SINUS TACHYCARDIA</b>			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>CARDIAC FAILURE</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nervous system disorders</b>			
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>CEREBRAL ISCHAEMIA</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>CEREBROVASCULAR ACCIDENT</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>EMBOLIC STROKE</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>EPILEPSY</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>GENERALISED TONIC-CLONIC SEIZURE</b>			

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MIGRAINE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
HEMIPARESIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INTRACRANIAL ANEURYSM				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INTRACRANIAL PRESSURE INCREASED				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
LUMBAR RADICULOPATHY				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HEADACHE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MIGRAINE WITH AURA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MULTIPLE SCLEROSIS				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MULTIPLE SCLEROSIS PSEUDO RELAPSE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
MULTIPLE SCLEROSIS RELAPSE				
subjects affected / exposed	4 / 486 (0.82%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
MUSCLE SPASTICITY				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
NERVOUS SYSTEM DISORDER				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OPTIC NEURITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PARALYSIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PARAPARESIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PARKINSON'S DISEASE				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PARTIAL SEIZURES WITH SECONDARY GENERALISATION				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
PRESYNCOPE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
SCIATICA				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
SEIZURE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
STATUS EPILEPTICUS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SUBARACHNOID HAEMORRHAGE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
TRANSIENT ISCHAEMIC ATTACK				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UHTHOFF'S PHENOMENON			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TRIGEMINAL NEURALGIA			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
SYNCOPE			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
AGRANULOCYTOSIS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANAEMIA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANAEMIA MEGALOBLASTIC			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
NEUTROPENIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
IRON DEFICIENCY ANAEMIA			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
LYMPHADENOPATHY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MICROCYTIC ANAEMIA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
FEBRILE NEUTROPENIA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
CATARACT			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
EPIRETINAL MEMBRANE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
EYE INFLAMMATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
GLAUCOMA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RETINAL DISORDER			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
APHTHOUS ULCER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL PAIN LOWER			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANAL FISSURE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANAL POLYP			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANORECTAL VARICES			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ABDOMINAL PAIN			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COLITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COLITIS ISCHAEMIC			

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
CONSTIPATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CROHN'S DISEASE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
DIARRHOEA			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
GASTRIC ULCER HAEMORRHAGE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
DUODENAL ULCER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DUODENAL ULCER HAEMORRHAGE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ENTEROCOLITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
FAECALOMA			

subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>GASTRIC FISTULA</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>DIVERTICULUM</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>GASTRITIS EROSIVE</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>GASTROINTESTINAL INFLAMMATION</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>GASTROINTESTINAL POLYP HAEMORRHAGE</b>				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>ILEUS</b>				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
<b>INCARCERATED UMBILICAL HERNIA</b>				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
<b>PANCREATITIS ACUTE</b>				

subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
INTESTINAL OBSTRUCTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LARGE INTESTINE POLYP				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NAUSEA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OESOPHAGEAL RUPTURE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
PANCREATITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
INGUINAL HERNIA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SMALL INTESTINAL OBSTRUCTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
UMBILICAL HERNIA				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
UPPER GASTROINTESTINAL HAEMORRHAGE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VOLVULUS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
VOMITING			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
CHOLECYSTITIS CHRONIC			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BILE DUCT STENOSIS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CHOLANGITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLECYSTITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLECYSTITIS ACUTE			

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
DRUG-INDUCED LIVER INJURY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
HEPATITIS ACUTE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HEPATITIS TOXIC			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CHOLELITHIASIS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
PRURITUS ALLERGIC			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
ACTINIC KERATOSIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DECUBITUS ULCER			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DERMATITIS			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
LICHEN PLANUS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RASH			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CALCULUS URINARY			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BLADDER PERFORATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
URETHRAL STENOSIS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
URINARY RETENTION			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CYSTITIS HAEMORRHAGIC			

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>TUBULOINTERSTITIAL NEPHRITIS</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>PROTEINURIA</b>			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>NEPHROLITHIASIS</b>			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>HYDRONEPHROSIS</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>HAEMATURIA</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Musculoskeletal and connective tissue disorders</b>			
<b>ARTHRALGIA</b>			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>BACK PAIN</b>			
subjects affected / exposed	4 / 486 (0.82%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
<b>CHONDROPATHY</b>			

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MUSCLE SPASMS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
RHABDOMYOLYSIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
OSTEOARTHRITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
POLYARTHRITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
MUSCULAR WEAKNESS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
ROTATOR CUFF SYNDROME			

subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SERONEGATIVE ARTHRITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPINAL PAIN			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
SPINAL STENOSIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
TENDONITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
ABSCCESS OF EYELID			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
ANAL ABSCESS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
APPENDICITIS			
subjects affected / exposed	2 / 486 (0.41%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
APPENDICITIS PERFORATED			

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ARTHRITIS INFECTIVE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ABSCESS LIMB				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
BACTERIAL INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
BACTERIAL PYELONEPHRITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
BORRELIA INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
BRONCHIOLITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
BRONCHITIS				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
COVID-19				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CANDIDA SEPSIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CELLULITIS			
subjects affected / exposed	3 / 486 (0.62%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
CHOLECYSTITIS INFECTIVE			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CLOSTRIDIUM DIFFICILE COLITIS			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CLOSTRIDIUM DIFFICILE INFECTION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
BURSITIS INFECTIVE			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19 PNEUMONIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
CYSTITIS			

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
DENGUE FEVER				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
DIVERTICULITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
ENCEPHALITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GASTROINTESTINAL INFECTION				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
ERYSIPELAS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
ESCHERICHIA URINARY TRACT INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GANGRENE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
GASTROENTERITIS				

subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
GASTROENTERITIS VIRAL				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
EPIDIDYMITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HEPATITIS VIRAL				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
HERPES OPHTHALMIC				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
IMPETIGO				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
INFECTED DERMAL CYST				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
INFLUENZA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ORCHITIS				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
LOWER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MASTITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
MENINGITIS ASEPTIC				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
MENINGITIS BACTERIAL				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
NEUTROPENIC SEPSIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
LARGE INTESTINE INFECTION				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
OSTEOMYELITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
OTITIS EXTERNA				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PELVIC INFLAMMATORY DISEASE				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PERITONITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA				
subjects affected / exposed	6 / 486 (1.23%)			
occurrences causally related to treatment / all	4 / 7			
deaths causally related to treatment / all	0 / 1			
PYELONEPHRITIS				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA BACTERIAL				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA ESCHERICHIA				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
POST PROCEDURAL INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
POST PROCEDURAL SEPSIS				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PYELOCYSTITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
PNEUMONIA ASPIRATION				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
PYELONEPHRITIS ACUTE				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
SEPSIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SEPTIC SHOCK				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SINUSITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SUSPECTED COVID-19				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
TOOTH INFECTION				

subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
URINARY TRACT INFECTION				
subjects affected / exposed	4 / 486 (0.82%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 0			
UROSEPSIS				
subjects affected / exposed	2 / 486 (0.41%)			
occurrences causally related to treatment / all	2 / 3			
deaths causally related to treatment / all	0 / 0			
VESTIBULAR NEURONITIS				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
VIRAL INFECTION				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
VIRAL PERICARDITIS				
subjects affected / exposed	1 / 486 (0.21%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
VIRAL UPPER RESPIRATORY TRACT INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
WOUND INFECTION				
subjects affected / exposed	0 / 486 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
ZIKA VIRUS INFECTION				

subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
DEHYDRATION			
subjects affected / exposed	1 / 486 (0.21%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
HYPONATRAEMIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DB PLACEBO	OLE OCRELIZUMAB	OLE PLACEBO
Total subjects affected by non-serious adverse events			
subjects affected / exposed	175 / 239 (73.22%)	318 / 369 (86.18%)	134 / 158 (84.81%)
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	19 / 239 (7.95%)	23 / 369 (6.23%)	9 / 158 (5.70%)
occurrences (all)	22	35	13
FALL			
subjects affected / exposed	0 / 239 (0.00%)	40 / 369 (10.84%)	16 / 158 (10.13%)
occurrences (all)	0	75	28
INFUSION RELATED REACTION			
subjects affected / exposed	61 / 239 (25.52%)	56 / 369 (15.18%)	40 / 158 (25.32%)
occurrences (all)	154	178	98
SKIN LACERATION			

subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	12 / 369 (3.25%) 14	8 / 158 (5.06%) 8
Vascular disorders HYPERTENSION subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	28 / 369 (7.59%) 33	12 / 158 (7.59%) 12
Nervous system disorders TRIGEMINAL NEURALGIA subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	8 / 369 (2.17%) 18	9 / 158 (5.70%) 14
DIZZINESS subjects affected / exposed occurrences (all)	10 / 239 (4.18%) 12	14 / 369 (3.79%) 17	10 / 158 (6.33%) 13
HEADACHE subjects affected / exposed occurrences (all)	31 / 239 (12.97%) 48	41 / 369 (11.11%) 73	15 / 158 (9.49%) 19
General disorders and administration site conditions FATIGUE subjects affected / exposed occurrences (all)	24 / 239 (10.04%) 32	24 / 369 (6.50%) 30	12 / 158 (7.59%) 14
ASTHENIA subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	21 / 369 (5.69%) 26	10 / 158 (6.33%) 11
OEDEMA PERIPHERAL subjects affected / exposed occurrences (all)	13 / 239 (5.44%) 16	22 / 369 (5.96%) 25	11 / 158 (6.96%) 12
PYREXIA subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	23 / 369 (6.23%) 39	14 / 158 (8.86%) 23
INFLUENZA LIKE ILLNESS subjects affected / exposed occurrences (all)	0 / 239 (0.00%) 0	25 / 369 (6.78%) 36	10 / 158 (6.33%) 13
Gastrointestinal disorders NAUSEA subjects affected / exposed occurrences (all)	15 / 239 (6.28%) 20	0 / 369 (0.00%) 0	0 / 158 (0.00%) 0

DIARRHOEA			
subjects affected / exposed	12 / 239 (5.02%)	42 / 369 (11.38%)	11 / 158 (6.96%)
occurrences (all)	15	54	15
CONSTIPATION			
subjects affected / exposed	12 / 239 (5.02%)	23 / 369 (6.23%)	8 / 158 (5.06%)
occurrences (all)	14	23	8
Respiratory, thoracic and mediastinal disorders			
COUGH			
subjects affected / exposed	8 / 239 (3.35%)	38 / 369 (10.30%)	12 / 158 (7.59%)
occurrences (all)	8	45	13
Skin and subcutaneous tissue disorders			
ECZEMA			
subjects affected / exposed	0 / 239 (0.00%)	14 / 369 (3.79%)	8 / 158 (5.06%)
occurrences (all)	0	17	8
RASH			
subjects affected / exposed	0 / 239 (0.00%)	23 / 369 (6.23%)	5 / 158 (3.16%)
occurrences (all)	0	24	6
Psychiatric disorders			
INSOMNIA			
subjects affected / exposed	15 / 239 (6.28%)	12 / 369 (3.25%)	10 / 158 (6.33%)
occurrences (all)	15	13	10
DEPRESSION			
subjects affected / exposed	31 / 239 (12.97%)	23 / 369 (6.23%)	9 / 158 (5.70%)
occurrences (all)	35	24	9
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	30 / 239 (12.55%)	57 / 369 (15.45%)	23 / 158 (14.56%)
occurrences (all)	39	73	36
BACK PAIN			
subjects affected / exposed	38 / 239 (15.90%)	54 / 369 (14.63%)	23 / 158 (14.56%)
occurrences (all)	54	70	30
MUSCLE SPASMS			
subjects affected / exposed	0 / 239 (0.00%)	19 / 369 (5.15%)	6 / 158 (3.80%)
occurrences (all)	0	21	6
PAIN IN EXTREMITY			

subjects affected / exposed occurrences (all)	25 / 239 (10.46%) 31	33 / 369 (8.94%) 38	18 / 158 (11.39%) 23
Infections and infestations			
INFLUENZA			
subjects affected / exposed	21 / 239 (8.79%)	39 / 369 (10.57%)	16 / 158 (10.13%)
occurrences (all)	25	59	21
BRONCHITIS			
subjects affected / exposed	15 / 239 (6.28%)	32 / 369 (8.67%)	11 / 158 (6.96%)
occurrences (all)	21	52	15
COVID-19			
subjects affected / exposed	0 / 239 (0.00%)	76 / 369 (20.60%)	21 / 158 (13.29%)
occurrences (all)	0	87	22
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	14 / 239 (5.86%)	56 / 369 (15.18%)	14 / 158 (8.86%)
occurrences (all)	21	110	17
TOOTH INFECTION			
subjects affected / exposed	0 / 239 (0.00%)	20 / 369 (5.42%)	2 / 158 (1.27%)
occurrences (all)	0	38	2
SINUSITIS			
subjects affected / exposed	0 / 239 (0.00%)	20 / 369 (5.42%)	6 / 158 (3.80%)
occurrences (all)	0	26	10
PNEUMONIA			
subjects affected / exposed	0 / 239 (0.00%)	25 / 369 (6.78%)	6 / 158 (3.80%)
occurrences (all)	0	34	6
NASOPHARYNGITIS			
subjects affected / exposed	63 / 239 (26.36%)	100 / 369 (27.10%)	48 / 158 (30.38%)
occurrences (all)	125	190	95
URINARY TRACT INFECTION			
subjects affected / exposed	57 / 239 (23.85%)	127 / 369 (34.42%)	44 / 158 (27.85%)
occurrences (all)	117	488	120

<b>Non-serious adverse events</b>	DB OCRELIZUMAB		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	400 / 486 (82.30%)		
Injury, poisoning and procedural complications			

CONTUSION			
subjects affected / exposed	14 / 486 (2.88%)		
occurrences (all)	19		
FALL			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
INFUSION RELATED REACTION			
subjects affected / exposed	194 / 486 (39.92%)		
occurrences (all)	496		
SKIN LACERATION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
Vascular disorders			
HYPERTENSION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
TRIGEMINAL NEURALGIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
DIZZINESS			
subjects affected / exposed	27 / 486 (5.56%)		
occurrences (all)	33		
HEADACHE			
subjects affected / exposed	68 / 486 (13.99%)		
occurrences (all)	98		
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	30 / 486 (6.17%)		
occurrences (all)	33		
ASTHENIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
OEDEMA PERIPHERAL			
subjects affected / exposed	24 / 486 (4.94%)		
occurrences (all)	27		

PYREXIA subjects affected / exposed occurrences (all)	0 / 486 (0.00%) 0		
INFLUENZA LIKE ILLNESS subjects affected / exposed occurrences (all)	0 / 486 (0.00%) 0		
Gastrointestinal disorders NAUSEA subjects affected / exposed occurrences (all)  DIARRHOEA subjects affected / exposed occurrences (all)  CONSTIPATION subjects affected / exposed occurrences (all)	18 / 486 (3.70%) 24  27 / 486 (5.56%) 43  25 / 486 (5.14%) 28		
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	35 / 486 (7.20%) 44		
Skin and subcutaneous tissue disorders ECZEMA subjects affected / exposed occurrences (all)  RASH subjects affected / exposed occurrences (all)	0 / 486 (0.00%) 0  0 / 486 (0.00%) 0		
Psychiatric disorders INSOMNIA subjects affected / exposed occurrences (all)  DEPRESSION subjects affected / exposed occurrences (all)	28 / 486 (5.76%) 31  34 / 486 (7.00%) 35		
Musculoskeletal and connective tissue disorders			

ARTHRALGIA			
subjects affected / exposed	56 / 486 (11.52%)		
occurrences (all)	66		
BACK PAIN			
subjects affected / exposed	59 / 486 (12.14%)		
occurrences (all)	71		
MUSCLE SPASMS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
PAIN IN EXTREMITY			
subjects affected / exposed	35 / 486 (7.20%)		
occurrences (all)	38		
Infections and infestations			
INFLUENZA			
subjects affected / exposed	57 / 486 (11.73%)		
occurrences (all)	76		
BRONCHITIS			
subjects affected / exposed	30 / 486 (6.17%)		
occurrences (all)	40		
COVID-19			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	60 / 486 (12.35%)		
occurrences (all)	87		
TOOTH INFECTION			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
SINUSITIS			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
PNEUMONIA			
subjects affected / exposed	0 / 486 (0.00%)		
occurrences (all)	0		
NASOPHARYNGITIS			

subjects affected / exposed	117 / 486 (24.07%)		
occurrences (all)	206		
URINARY TRACT INFECTION			
subjects affected / exposed	103 / 486 (21.19%)		
occurrences (all)	255		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 March 2011	Clarification of the implementation of 2 separate infusions 14 days apart throughout the study. Revision of inclusion / exclusion criteria. Addition of plasma and urine sample collection for JC Virus.
09 April 2012	This version was not issued and was superseded by protocol WA25046 Version D.
15 June 2012	Provision of greater clarity in the protocol language around expedited reporting of serious adverse events (SAEs) to the Sponsor to a time interval of no longer than 24 hours. Addition of wording to the safety section. Revision of the dosing preparation and infusion guidance to simplify the procedures.
06 February 2015	Inclusion of more detail with respect to the OLE phase. Inclusion of an update to the Statistical Considerations and Analytical Plan section of the protocol in line with the Statistical Analysis Plan (SAP) for the study:
23 March 2016	Objectives and dosing regimen of the OLE phase were clarified in this update. New note that for patients that withdraw from treatment with ocrelizumab and enter Safety Follow-Up, alternative treatments for their MS as judged clinically appropriate by the Treating Investigator are allowed.
24 September 2017	Updates to the core safety wording; Additional wording changes were made to align with the most recent version of the core safety text; Addition of Adverse Events of Special Interest (AESI)
03 August 2018	Addition of optional collection of biosamples for the Research Biosample Repository taken at a single timepoint during the OLE Phase; Extension of the WA25046 OLE treatment phase to 31 December 2020; Updated language pertaining to impairment of vaccination response
17 December 2019	The WA25046 open-label extension (OLE) treatment phase has been extended to 31 December 2022
30 July 2020	Amended to incorporate the option of a shorter study drug infusion regimen. The goal of this amendment is to reduce patient burden and facilitate patient management at the infusion center during the ongoing open-label extension phase.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported